Sermorelin vs GHRP-2: Head-to-Head Comparison
Sermorelin (GHRH pathway) and GHRP-2 (ghrelin pathway) stimulate GH through different receptor systems. Sermorelin has a longer clinical history with former FDA approval, while GHRP-2 provides a stronger acute GH pulse. They are often combined for synergistic GH release.
Side-by-Side Comparison
| Dimension | Sermorelin | GHRP-2 |
|---|---|---|
| Evidence Level | Formerly FDA-approved; extensive clinical data | Extensive clinical research |
| FDA Status | Previously FDA-approved | Not approved |
| Mechanism | GHRH receptor agonist | Ghrelin receptor (GHS-R1a) agonist |
| GH Release Pattern | Physiological pulsatile release | Strong acute GH pulse |
| Side Effects | Flushing, headache, injection site pain | Hunger, cortisol/prolactin increase |
| Half-Life | ~10-20 minutes | ~15-60 minutes |
Peptide Overviews
Sermorelin
AFDA ApprovedSermorelin is the shortest fully functional fragment of GHRH (amino acids 1-29). It was the first GHRH analog approved by the FDA, marketed as Geref for diagnostic and therapeutic use.
GHRP-2
BHuman StudiesGHRP-2 is a synthetic hexapeptide growth hormone secretagogue. It is one of the most potent GHRPs and has been used in clinical research for GH deficiency diagnosis.
Sermorelin vs GHRP-2: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.